Document:

Exhibit 10.1

March 3, 2006

AMCON Distributing Company
7405 Irvington Road
Omaha, Nebraska 68122

And

Chamberlin Natural Foods, Inc.
430 North Orlando Avenue
Winter Park, Florida 32789

And

Hawaiian Natural Water Company, Inc.
98-746 Kuahao Place
Pearl City, Hawaii 96782

And

Health Food Associates, Inc.
7807 East 51st Street
Tulsa, Oklahoma 74145

And

Trinity Springs, Inc.
1101 West River Street
Suite 370
Boise, Idaho 83702

Re:  Sixth Amendment to Amended and Restated Loan and Security Agreement
(this "Amendment")

Gentlemen:

AMCON Distributing Company, a Delaware corporation, ("AMCON"), Chamberlin
Natural Foods, Inc., a Florida corporation, ("Chamberlin Natural"), Hawaiian
Natural Water Company, Inc., a Delaware corporation, ("Hawaiian Natural"),
Health Food Associates, Inc., an Oklahoma corporation, ("Health Food"), and
Trinity Springs, Inc., a Delaware corporation, ("Trinity Springs"), (AMCON,
Chamberlin Natural, Hawaiian Natural, Health Food, and Trinity Springs are
each referred to as a "Borrower" and are collectively referred to as
"Borrowers") and LaSalle Bank National Association, a national banking
association (in its individual capacity, "LaSalle"), as agent (in such
capacity as agent, "Agent") for itself, Gold Bank, a Kansas state bank, and
all other lenders from time to time party to the Loan Agreement referred to
below ("Lenders"), have entered into that certain Amended and Restated Loan
and Security Agreement dated September 30, 2004 (the "Loan Agreement").  From

time to time thereafter, Borrowers, Agent and Lenders may have executed
various amendments (each an "Amendment" and collectively the "Amendments") to
the Loan Agreement (the Loan Agreement and the Amendments hereinafter are
referred to, collectively, as the "Agreement").  Borrowers, Agent and Lenders
now desire to further amend the Agreement as provided herein, subject to the
terms and conditions hereinafter set forth.

NOW, THEREFORE, in consideration of the foregoing recitals, the mutual
covenants and agreements set forth herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows:

  1.  The Agreement hereby is amended as follows:

      a.  Subsection 1 of the Agreement is amended by adding thereto in
alphabetical order the following definition of "Excess Availability":

          "Excess Availability" shall mean, as of any date of determination
by Agent, the excess, if any, of the lesser of (i) the Maximum Revolving Loan
Limit less the sum of the outstanding Revolving Loans and Letter of Credit
Obligations and (ii) the Revolving Loan Limit less the sum of the outstanding
Revolving Loans and Letter of Credit Obligations, in each case as of the
close of business on such date and assuming, for purposes of calculation,
that all accounts payable which remain unpaid more than thirty (30) days
after the due dates thereof as the close of business on such date are treated
as additional Revolving Loans outstanding on such date.

      b.  Subsection 13(d) of the Agreement is amended and restated in full,
to read as follows:

         (d)  Mergers, Sales, Acquisitions, Subsidiaries and Other
Transactions Outside the Ordinary Course of Business.

         No Borrower shall (i) enter into any merger or consolidation; (ii)
change its state of organization or enter into any transaction which has the
effect of changing its state of organization; (iii) sell, lease or otherwise
dispose of any of its assets other than in the ordinary course of business,
provided that AMCON may sell and dispose of assets with a value of less than
$250,000.00 in any transaction, or series of related transactions, provided
that the proceeds thereof, net of reasonable out of pocket disposition
expenses, are applied to the Liabilities; (iv) purchase the stock, other
equity interests or all or a material portion of the assets of any Person or
division of such Person; or (v) enter into any other transaction outside the
ordinary course of such Borrower's business, including, without limitation,
any issuance of any shares of, or warrants or other rights to receive or
purchase any shares of, any class of its stock or any other equity interest
other than (I) such issuances pursuant to the terms of such Borrower's stock

                                     2

option plan, (II) the issuance by AMCON of Series B Preferred Stock so long
as the entire proceeds thereof are used to repay the existing subordinated
indebtedness of AMCON, and (III) the issuance by AMCON of 80,000 shares of
Series C Convertible Preferred Stock to Draupnir Capital, LLC ("Draupnir")
pursuant to that certain Securities Purchase Agreement dated as of March 3,
2006 between AMCON and Draupnir so long as the entire proceeds thereof are
used to pay the Revolving Loans.  Notwithstanding anything in this Agreement
to the contrary, no Borrower shall redeem, retire, purchase or otherwise
acquire any shares of any class or series of its stock or any other equity
interest (including, without limitation, any shares of AMCON's Series A
Preferred Stock, Series B Preferred Stock or Series C Convertible Preferred
Stock); provided, however, that (i) AMCON may redeem odd lot stock (other
than AMCON's Series C Convertible Preferred Stock) in an aggregate amount not
to exceed $50,000.00 in any calendar year and other stock (other than AMCON's
Series C Convertible Preferred Stock) up to $100,000.00 in the aggregate
during any calendar year, and (ii) AMCON may redeem shares of AMCON's Series
C Convertible Preferred Stock only so long as (I) no Event of Default is in
existence at the time of, or would occur after giving effect to, any such
redemption, and (II) Borrowers shall have Excess Availability of not less
than Two Million Dollars ($2,000,000.00) after giving effect to any such
redemption.  No Borrower shall form any Subsidiaries or enter into any joint
ventures or partnerships with any other Person.

      c.  Subsection 13(e) of the Agreement is amended and restated in full,
to read as follows:

         (e)  Dividends and Distributions.

          No Borrower shall declare or pay any dividend or other distribution
(whether in cash or in kind) on any class of its stock (if such Borrower is a
corporation) or on account of any equity interest in such Borrower (if such
Borrower is a partnership, limited liability company or other type of
entity).  Notwithstanding the foregoing and provided that (i) each such
dividend payment is permitted under all applicable laws; and (ii) no Event of
Default shall have occurred prior to, or would occur as a result of, any such
dividend payment, AMCON may pay the regularly scheduled dividends on its (w)
Common Stock in an aggregate amount not to exceed $.72 per share in any
Fiscal Year, (x) Series A Preferred Stock in accordance with the terms of
such stock in an aggregate amount not to exceed $172,000 in any Fiscal Year,
(y) Series B Preferred Stock in accordance with the terms of such stock in an
aggregate amount not to exceed $140,000 in any Fiscal Year, and (z) Series C
Convertible Preferred Stock in accordance with the terms of the Series C
Certificate of Designations (as defined below) in an aggregate amount not to
exceed $120,000 in any Fiscal Year.  Without limitation of the foregoing,
AMCON hereby agrees not to accelerate, increase or prepay said dividends with
respect to its Series A Preferred Stock, Series B Preferred Stock or Series C
Convertible Preferred Stock.

                                     3

      d.  Subsection 13(g) of the Agreement is amended and restated in full,
to read as follows:

          (g)  Fundamental Changes, Line of Business.

          Except for the filing by AMCON of (i) a Certificate of Designation
for the Series B Preferred Stock and any restatements and amendments to
AMCON's certificate of incorporation to physically reflect the Certificates
of Designation for the Series A Preferred Stock and the Series B Preferred
Stock, and (ii) a Certificate of Designations, Preferences and Rights of
Series C Convertible Preferred Stock of AMCON dated as of March 3, 2006 (the
"Series C Certificate of Designations") and any restatements and amendments
to AMCON's certificate of incorporation to physically reflect the Series C
Certificate of Designations for the Series C Convertible Preferred Stock, no
Borrower shall amend its organizational documents or change its Fiscal Year
or enter into a new line of business materially different from such
Borrower's current business.

  2.  This Amendment shall not become effective until each of the following
conditions precedent has been satisfied:

      a.  Agent shall have received this Amendment, duly executed by the
parties hereto;

      b.  Agent shall have received a true, correct and complete copy of that
certain Securities Purchase Agreement dated as of March 3, 2006 between AMCON
and Draupnir Capital, LLC (the "Securities Purchase Agreement"), together
with all exhibits and schedules thereto, all in form and substance
satisfactory to Agent, duly executed by the parties thereto, certified by an
officer of AMCON; and

      c.  Agent shall have received from AMCON to pay the Revolving Loans all
of the proceeds from the issuance and sale by AMCON of shares of Series C
Convertible Preferred Stock pursuant to the Securities Purchase Agreement and
such proceeds shall have been no less than $2,000,000.00.

  3.  The representations and warranties set forth in Section 11 of the
Agreement shall be deemed remade as of the date hereof by each Borrower,
except that any and all references to the Agreement in such representations
and warranties shall be deemed to include this Amendment.  No Event of
Default has occurred and is continuing and no event has occurred and is
continuing which, with the lapse of time, the giving of notice, or both,
would constitute an Event of Default under the Agreement.

  4.  Borrowers agree to pay on demand all costs and expenses of or incurred
by Agent (including, but not limited to, legal fees and expenses) in
connection with the negotiation, preparation, execution and delivery of this
Amendment.

                                     4

  5.  This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original, and all of which together shall constitute
one and the same instrument.

  6.  Except as expressly amended hereby, the Agreement and the Other
Agreements are hereby ratified and confirmed by the parties hereto and remain
in full force and effect in accordance with the terms thereof.  Each Borrower
hereby reaffirms its grant of the security interest in the Collateral.

  7.  This Amendment shall be governed by and construed under the laws of the
State of Illinois, without regard to conflict of laws principles of such
State.

LASALLE BANK NATIONAL ASSOCIATION,
a national banking association,
as Agent and a Lender

By: /s/ Mitchell Rasky
    ------------------
        Mitchel Rasky
Title:  Sr. Vice President

GOLD BANK,
a Kansas state bank,
as a Lender

By: /s/ Mark Jannaman
    -----------------
        Mark Jannaman
Title:  Vice President

ACKNOWLEDGED AND AGREED TO this 3rd day of March, 2006:

AMCON DISTRIBUTING COMPANY

By: /s/ Michael D. James
    --------------------
        Michael D. James
Title:  Vice President and Chief Financial Officer

HAWAIIAN NATURAL WATER COMPANY, INC.

By: /s/ Michael D. James
    --------------------
        Michael D. James
Title:  Secretary

                                     5

CHAMBERLIN NATURAL FOODS, INC.

By: /s/ Michael D. James
    --------------------
        Michael D. James
Title:  Secretary

HEALTH FOOD ASSOCIATES, INC.

By: /s/ Michael D. James
    --------------------
        Michael D. James
Title:  Secretary

TRINITY SPRINGS, INC.

By: /s/ Michael D. James
    --------------------
        Michael D. James
Title:  Asst. Secretary

Consented and agreed to by the following guarantor(s) of the obligations of
AMCON DISTRIBUTING COMPANY, HAWAIIAN NATURAL WATER COMPANY, INC., CHAMBERLIN
NATURAL FOODS, INC., and HEALTH FOOD ASSOCIATES, INC. to LaSalle Bank
National Association, as Agent.

/s/ William F. Wright
---------------------
William F. Wright
Date:  March 3, 2006

                                     6exv10w76

 

Exhibit 10.76

EMPLOYMENT AGREEMENT

     THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of [DATE] (the “Effective Date”) by and
between Gen-Probe Incorporated, a Delaware corporation with offices at 10210 Genetic Center Drive,
San Diego, California 92121 (“Gen-Probe”), and [NAME] (the “Executive”).

     WHEREAS, the Executive is currently employed as an officer of Gen-Probe;

     WHEREAS, prior to September 15, 2002, Gen-Probe was a wholly-owned subsidiary of Chugai
Pharmaceutical Co., Ltd.;

     WHEREAS, Chugai distributed its Gen-Probe shareholdings to its shareholders in a “spin off”
transaction on September 15, 2002; and

     WHEREAS, the Board of Directors of Gen-Probe (the “Board”), having considered the proposed
spin-off transaction and other circumstances, deems it in the best interest of Gen-Probe to offer
this Agreement to the Executive and the Executive desires to enter into this Agreement.

     ACCORDINGLY, the parties hereto agree as follows:

	1.	 	Term of Employment. This Agreement shall be immediately effective. This Agreement,
and Executive’s employment hereunder, shall be for an indefinite term. At any time during the
term of this Agreement, either party may terminate this Agreement, and Executive’s employment,
in accordance with the provision of Sections 6 and 7 of this Agreement.
	 
	2.	 	Position and Duties. The Executive shall serve as [TITLE] of Gen-Probe, and shall
have commensurate responsibilities and authority. The Board of Directors may from time to
time particularly specify the Executive’s duties and authority. The Executive shall not
engage in or perform duties for any other persons or entities that interfere with the
performance of his duties hereunder. Any outside board of director positions held by the
Executive will be subject to approval by the Board of Directors of Gen-Probe.

1

 

	3.	 	Salary, Bonus and Benefits. 

	 	(a)	 	Salary. During the period of the Executive’s employment, Gen-Probe
shall pay him an annual base salary at the rate the Executive is being paid as of the
Effective Date. This base salary may be adjusted annually by the Board, subject to the
terms of this Agreement and consistent with the Executive’s performance and
Gen-Probe’s policy regarding adjustments in officer compensation established from time
to time by the Board.
	 
	 	(b)	 	Bonus. In addition, at the Board’s discretion, the Executive may be
awarded incentive compensation, in the form of a cash bonus for each fiscal year
during his employment, based upon performance.
	 
	 	(c)	 	Benefits. The Executive shall be entitled to participate in the
employee benefit programs (including but not limited to medical, dental, life and
disability insurance, 401K retirement plan, and vacation program), which may be
adopted and maintained by Gen-Probe. The Executive may receive such other and
additional benefits as the Board may determine from time to time in its sole
discretion.

	4.	 	Expense Reimbursement. The Executive shall be entitled to receive prompt
reimbursement for all reasonable and customary expenses incurred by him in performing services
hereunder, including all expenses of travel and living expenses while away from home on
business or at the request of, and in the service of Gen-Probe; provided, that such expenses
are incurred and accounted for in accordance with the policies and procedures established by
Gen-Probe.
	 
	5.	 	Indemnification. Gen-Probe shall indemnify the Executive to the maximum extent
permitted by law and by the by-laws of Gen-Probe if the Executive is made a party, or
threatened to be made a party, to any threatened or pending legal action, suit or proceeding,
whether civil, criminal, administrative or investigative, by reason of the fact that the
Executive is or was an officer, director or employee of Gen-Probe or any subsidiary or
affiliate thereof, in which capacity the Executive is or was serving at Gen-Probe’s request,
against reasonable expenses (including reasonable attorneys’ fees), judgments, fines and
settlement payments incurred by him in connection with such action, suit or proceeding.
	 
	6.	 	Termination. The Executive may terminate his employment hereunder at any time, with
or without Good Reason (as defined below) upon written notice to Gen-Probe. If Executive
contends that Good Reason exists for his termination, such notice shall specifically and
expressly state the grounds which he contends constitute Good Reason. Gen-Probe may terminate
the Executive’s employment hereunder at any time, subject to the terms of this Agreement, with
or without Cause (as defined below) upon written notice to the Executive. If this Agreement
is terminated, all compensation and benefits other than severance benefits

2

 

	 	 	described in Section 7 below, to the extent applicable, shall immediately cease, except
that the Executive will be entitled, through the date of termination, to payment of his
salary and benefits under Gen-Probe benefit programs and plans in accordance with their
terms.

As used in this Agreement, “Good Reason” shall mean any of the following events that are
not consented to by the Executive: (i) a substantial and material diminution in the
Executive’s duties and responsibilities hereunder; (ii) the location of the Executive’s
assignment on behalf of Gen-Probe is moved to a location more than 30 miles from its
present location; (iii) a reduction of more than ten percent (10%) in the Executive’s base
salary or in the Executive’s benefits received from Gen-Probe; (iv) the failure of
Gen-Probe to obtain a satisfactory agreement from any other successor to Gen-Probe to
assume and agree to perform this Agreement; or (iv) a material breach by Gen-Probe of its
obligations under this Agreement after notice in writing from the Executive and a
reasonable opportunity for Gen-Probe to cure or substantially mitigate any material adverse
effect of such breach. The Executive’s consent to any event which would otherwise
constitute Good Reason shall be conclusively presumed if the Executive does not exercise
his rights to terminate this Agreement for Good Reason under this section within ninety
(90) days of notice of the event.

As used in this Agreement, “Cause” shall mean any of the following events: (i) any act of
gross or willful misconduct, fraud, misappropriation, dishonesty, embezzlement or similar
conduct on the part of Executive; (ii) the Executive’s conviction of a felony or any
crime involving moral turpitude (which conviction, due to the passage of time or otherwise,
is not subject to further appeal); (iii) the Executive’s misuse or abuse of alcohol, drugs
or controlled substances and failure to seek and comply with appropriate treatment; (iv)
willful and continued failure by the Executive to substantially perform his duties under
this Agreement (other than any failure resulting from disability or from termination by the
Executive for Good Reason) as determined by a majority of the Board after written demand
from the Board of Directors for substantial performance is delivered to the Executive, and
the Executive fails to resume substantial performance of his duties on a continuous basis
within 30 days of such notice; (vi) the death of the Executive; or (vii) the Executive
becoming disabled such that he is not able to perform his usual duties for Gen-Probe for a
period in excess of six (6) consecutive calendar months.

3

 

	7.	 	Severance Benefits in Certain Events. If Gen-Probe terminates the Executive’s
employment for reasons other than Cause, or if the Executive terminates his employment for
Good Reason, the Executive shall be entitled to receive as liquidated damages, the following
severance benefits:

	 	(a)	 	Salary. The Executive shall continue to receive his base salary, at
the rate in effect at the time of his termination of employment, in monthly
installments commencing the first day of the first month following termination and
continuing for an aggregate period of twelve (12) months (the “Salary Continuation
Period”); provided, however, that if termination under this Section 7 occurs in
connection with a Change in Control, then the Executive shall receive a single lump
sum payment, payable within 10 days of termination, equal to eighteen (18)
months’ base salary.
	 
	 	 	 	For purposes of this Agreement, “Change in Control” shall have the meaning set forth on
Attachment “1” to this Agreement (hereby incorporated by reference). For purposes of
this Agreement, a termination shall be “in connection with” a Change in Control if
termination occurs within the period six (6) months prior to or eighteen (18) months
after a Change in Control.
	 
	 	(b)	 	Bonus. If termination under this Section 7 occurs in connection
with a Change in Control then the Executive shall be entitled to receive, in lieu of
the bonus provided in Section 3(b) and in addition to the salary payment described in
Section 7(a), above, an amount equal to 1.5 times the greater of (i) the Executive’s
targeted level bonus in the year of the termination, or (ii) the Executive’s highest
discretionary bonus in the preceding three years. The amount payable shall be paid in
the same manner as and on the same schedule as the salary compensation paid under
subsection (a) above. No bonus compensation shall be payable under this section 7
unless termination occurs in connection with a change in control.
	 
	 	 	 	(c) Health Care and Life Insurance Coverage. Continued health care coverage
under Gen-Probe’s medical plan will be provided, without charge, to the Executive and
his eligible dependents until the earlier of (i) one (1) year following the
termination date or (ii) the first date that the Executive is covered under another
employer’s health benefit program providing substantially the same or better benefit
options to the Executive without exclusion for any pre-existing medical condition.
The period of time medical coverage continues under this agreement will be counted as
coverage time under COBRA. Gen-Probe will pay the premium for continued life
insurance coverage, if any, that the Executive may have elected under Gen-Probe’s Life
Insurance and Supplemental Life Insurance plan, subject to payment by the Executive of
the portion of such premium not contributed by Gen-Probe under such plan, during the
Salary Continuation Period.

4

 

	 	(d)	 	401(k) Plan. The Executive’s interest in any unvested contributions
made by Gen-Probe to the Executive’s 401(k) account shall vest as of the date of
termination.
	 
	 	(e)	 	Outplacement Services. Gen-Probe agrees to provide Executive with
outplacement services during the first six months of the Salary Continuation Period.
	 
	 	(f)	 	Tax Matters. All compensation described in this Section 7 will be
subject to Gen-Probe’s collection of all applicable federal, state and local income
and employment withholding taxes. If any excise tax is imposed under Section 4999 in
connection with the compensation described in this Section 7 and/or in connection with
the acceleration upon severance of any stock options granted by Gen-Probe to the
Executive, Executive shall be solely responsible for any such excise tax.
	 
	 	(g)	 	Release of Claims. Gen-Probe’s obligation to make the payments and
provide the benefits hereunder shall be conditioned upon Executive’s execution of a
release of all claims, in standard form and content. The release shall be mutual and
shall also be signed on behalf of Gen-Probe.

	8.	 	Miscellaneous. 

	 	(a)	 	Arbitration. Executive and Gen-Probe agree that any and all claims or
disputes that in any way relate to or arise out of Executive’s employment with
Gen-Probe or the termination of such employment (including but not limited to claims
under this Agreement or any other contract, tort claims, and statutory claims of
employment discrimination, retaliation or harassment) shall be resolved exclusively
through final and binding arbitration in San Diego, California. Executive and
Gen-Probe waive any rights to a jury trial in connection with such claims or disputes.
The costs of the arbitration, including the fees of the arbitrator, shall be borne
exclusively by Gen-Probe. Any such arbitration shall take place in San Diego,
California and shall be conducted by a single neutral arbitrator who shall be a
retired federal or state judge, to be appointed by Judicial Arbitration and Mediation
Services (“JAMS”) in accordance with JAMS rules. The applicable procedural rules of
JAMS shall govern the arbitration. The arbitrator’s decision shall be delivered in
writing and shall disclose the essential findings and conclusion on which the
arbitrator’s decision is based. The parties shall be permitted to conduct adequate
discovery to allow for a full and fair exploration of the issues in dispute in the
arbitration proceeding. The arbitrator may grant any relief which otherwise would have
been available to the parties in a court proceeding. The decision and award of the
arbitrator shall be final and binding, and judgment upon the arbitrator’s award may be
entered by any court of competent jurisdiction.

5

 

	 	(b)	 	Governing Law. This Agreement shall be construed and enforced in
accordance with and be governed by the laws of the State of California.
	 
	 	(c)	 	Entire Agreement. This Agreement sets forth the entire Agreement and
understanding between the Executive and the Company on the subject matter hereof, and
supersedes any other negotiations, agreements, understandings, oral agreements,
representations and past or future practices whether written or oral. No provision of
this Agreement may be amended, supplemented, modified, cancelled, or discharged unless
such amendment, supplement, modification, cancellation or discharge is agreed to, in
writing, signed by the Executive and a duly authorized officer of the Company (other
than the Executive); and no provisions hereof may be waived, except in writing, so
signed by or on behalf of the party granting such waiver.
	 
	 	(d)	 	Validity. The invalidity or unenforceability of any provision or
provisions of this Agreement shall not affect the validity or enforceability of any
other provision of this Agreement, which shall remain in full force and effect.
	 
	 	(e)	 	Notices.  For the purposes of this Agreement, notices, demands and
all other communications provided for in this Agreement shall be in writing and shall
be deemed to have duly given when personally delivered or mailed by United States
certified or registered mail, return receipt requested, postage prepaid, addressed as
follows:

If to the Executive:

[ADDRESS]

If to Gen-Probe:

President and Chief Executive Officer

Gen-Probe Incorporated

10210 Genetic Center Drive

San Diego, California 92121

With a copy to:

Vice President, Administration

Gen-Probe Incorporated

10210 Genetic Center Drive

San Diego, California 92121

6

 

	 	(f)	 	Successors. Gen-Probe will require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or substantially all
the business and/or assets of Gen-Probe, by agreement in form and substance
satisfactory to the Executive, expressly to assume and agree to perform this Agreement
in the same manner and to the same extent that Gen-Probe would be required to perform
it if no such succession had taken place. This Agreement and all rights under the
Agreement shall be binding upon and shall inure to the benefit of and be enforceable
by the party’s personal or legal representatives, executors, administrators, heirs,
and successors.
	 
	 	(g)	 	No Right to Continued Employment. Nothing herein shall be construed
as giving the Executive any rights to continued employment with Gen-Probe, and
Gen-Probe shall continue to have the right to terminate the Executive’s employment at
any time, with or without cause, subject to the provisions of this Agreement.
	 
	 	In witness whereof, the parties have executed this Agreement.

	 	 	 	 	 	 	 	 	 
	Executive:	 	 	 	Gen-Probe Incorporated:	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By
	 	 

	 	 
	[NAME]	 	 	 	Henry L. Nordhoff	 	 
	 	 	 	 	Chairman, President and Chief Executive Officer	 	 

7

 

ATTACHMENT “1”

DEFINITION OF “CHANGE IN CONTROL”

          Change in Control. “Change in Control” shall mean a change in ownership or control of the
Company effected through any of the following transactions:

          (a) any person or related group of persons (other than the Company or a person that,
prior to such transaction, directly or indirectly controls, is controlled by, or is under
common control with, the Company) directly or indirectly acquires beneficial ownership
(within the meaning of Rule 13d-3 under the Exchange Act) of securities possessing more
than fifty percent (50%) of the total combined voting power of the Company’s outstanding
securities by means of any transaction or series of transactions; or

          (b) there is a change in the composition of the Board over a period of thirty-six
(36) consecutive months (or less) such that a majority of the Board members (rounded up to
the nearest whole number) ceases, by reason of one or more proxy contests for the election
of Board members, to be comprised of individuals who either (i) have been Board members
continuously since the beginning of such period or (ii) have been elected or nominated for
election as Board members during such period by at least a majority of the Board members
described in clause (i) who were still in office at the time such election or nomination
was approved by the Board; or

          (c) the stockholders of the Company approve a merger or consolidation of the Company
with any other corporation (or other entity), other than a merger or consolidation which
would result in the voting securities of the Company outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity or another entity) more than 66-2/3% of the combined
voting power of the voting securities of the Company or such surviving entity outstanding
immediately after such merger or consolidation; provided, however, that a
merger or consolidation effected to implement a recapitalization of the Company (or
similar transaction) in which no person acquires more than 25% of the combined voting
power of the Company’s then outstanding voting securities shall not constitute a Change in
Control; or

          (d) the stockholders of the Company approve a plan of complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or substantially
all of the Company’s assets.

8

 

Schedule to Exhibit 10.76

The preceding form of Employment Agreement was entered into between the Company and the following
individuals:

	 	 	 	 	 
	Name	 	Title	 	Execution Date
	Niall Conway

	 	Executive Vice President – Sales and Operations
	 	November 12, 2002
	Daniel L. Kacian

	 	Executive Vice President and Chief Scientist
	 	November 12, 2002
	R. William Bowen

	 	Vice President and General Counsel
	 	November 12, 2002
	Glen Paul Freiberg

	 	Vice President – Regulatory, Quality &
Government Affairs
	 	November 12, 2002
	Stephen J. Kondor

	 	Vice President – Sales and Marketing
	 	July 29, 2005
	Lynda A. Merrill

	 	Vice President – Industrial Relationships
	 	January 1, 2004
	Larry T. Mimms

	 	Executive Vice President – Research and Development
	 	November 12, 2002
	Herm Rosenman

	 	Vice President, Finance and Chief Financial Officer
	 	November 12, 2002
	Diane De Walt

	 	Vice President – Human Resources
	 	January 3, 2005
	Martin
B. Edelshain

	 	Vice President –
Strategic Planning and Business Development
	 	November 11, 2003

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]